News

The German Federal Institute for Medicines and Medical Devices (BfArM) has confirmed that the medicines verification system in Germany has detected a counterfeit versions of medicine Ozempic®, which were promptly removed from circulation and has not reached the patients.

Intermarket transactions (IMTs) are a core part of the EMVS but present their own unique challenges.

The European Medicines Verification Organisation (EMVO) has launched a newsletter, which informs about the statement from EMVO’s new President, the roles and responsibilities of the National Medicines Verification Organisations (NMVO) Observers, the experience from the Hungarian Medicines Verification Organisation in ending the stabilisation period, the Belgium's experience with the Nordic recommendations on the recalls of batches and withdrawal of products, as well as on the status of alerts in the European Medicines Verification System (EMVS).

European Medicines Verification Organisation (EMVO) would like to highlight once again the consequences following Product Withdrawal and Batch recall and remind you that these are irreversible actions.

On May 12, at the European Medicines Verification Organisation’s (EMVO) General Assembly meeting, the NMVO Observers within EMVO’s Board for 2023 from the National Medicines Verification Organizations (NMVOs) were approved. As one of the observers representing the group of small-scale countries, will be the Latvian Medicines Verification Organisation (LZVO) and its Chairwoman of the Board Inese Erdmane.

The European Medicines Verification Organisation (EMVO) has launched a newsletter, which looks back on the past four years of the verification system’s operation, informs about the launch of the European Alert Management System (EAMS) and provides an opportunity to look into the first European Medicines Verification System’s (EMVS) forum, which was also attended by the Latvian Medicines Verification Organisation (LZVO) representatives Inese Erdmane and Andra Pučko.